Exemestane: A review of its use in postmenopausal women with breast cancer

Drugs

Volumn 69, Issue 7, 2009, Pages 889-918

  Deeks, Emma D ^a   Scott, Lesley J ^b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

Aromatase inhibitors; Breast cancer; Exemestane; Pharmacodynamics; Pharmacoeconomics; Pharmacokinetics; Postmenopausal; Therapeutic use; Tolerability

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; EXEMESTANE; FULVESTRANT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; KETOCONAZOLE; LETROZOLE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEGESTROL; PLACEBO; RIFAMPICIN; SEX HORMONE BINDING GLOBULIN; TAMOXIFEN; TRIACYLGLYCEROL;

ADJUVANT THERAPY; ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTHRITIS; ARTICLE; ASTHENIA; BLOOD CLOT LYSIS; BLOOD LEVEL; BODY FAT; BONE DENSITY; BONE PAIN; BREAST CANCER; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CARPAL TUNNEL SYNDROME; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; CREATININE CLEARANCE; DIARRHEA; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; FATIGUE; FRACTURE; GYNECOLOGIC DISEASE; HEART DEATH; HEART INFARCTION; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; HYPERTENSION; INJECTION SITE PAIN; INJECTION SITE REACTION; INSOMNIA; ISCHEMIC HEART DISEASE; JOINT STIFFNESS; LETHARGY; LIBIDO DISORDER; LIMB PAIN; MALAISE; MAXIMUM PLASMA CONCENTRATION; MENOPAUSAL SYNDROME; MUSCLE CRAMP; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NONHUMAN; OSTEOPOROSIS; PAIN; PARESTHESIA; POSTMENOPAUSE; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; SEXUAL AROUSAL; SEXUAL DYSFUNCTION; SIDE EFFECT; SWEATING; THROMBOCYTOPENIA; TREATMENT OUTCOME; UTERUS MYOMA; VAGINA BLEEDING; VAGINA DISCHARGE; VAGINAL DRYNESS; VAGINITIS; VEIN THROMBOSIS; VOMITING; WEIGHT GAIN;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; POSTMENOPAUSE;

EID: 66149083574     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200969070-00007     Document Type: Article

References (101)

1. American Cancer Society. Global cancer facts and figures 2007 [online]. Available from URL: http://www.cancer.org/ downloads/STT/Global-Cancer-Facts- and-Figures-2007- rev.pdf [Accessed 2008 Jul 30]
2. Travis RC, Key TJ. Oestrogen exposure and breast cancer risk. Breast Cancer Res 2003 Jul 28; 5 (5): 239-47
3. Foster PA. Steroid metabolism in breast cancer. Minerva Endocrinol 2008 Mar; 33 (1): 27-37
4. Suzuki T, Miki Y, Nakamura Y, et al. Sex steroid- producing enzymes in human breast cancer. Endocr Relat Cancer 2005 Dec; 12 (4): 701-20
5. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Eng J Med 2003 Jun 12; 348 (24): 2431-42
6. Rugo HS. The breast cancer continuum in hormone- receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase in- hibitors. Annal Oncol 2008 Jan; 19 (1): 16-27
7. Pharmacia Ltd. Aromasin- 25mg coated tablets: summary of product characteristics [online]. Available from URL: http://www.emc.medicines.org.uk [Accessed 2009 Mar 13]
8. Pharmacia and Upjohn Co. Aromasin- exemestane tablets: US prescribing information [online]. Available from URL: http://www.pfizer.com/files/products/ uspi- aromasin.pdf [Accessed 2009 Apr 28]
9. Moen MD, Wagstaff AJ. Exemestane: a review of its use as adjuvant treatment for early breast cancer in post- menopausal women. Am J Cancer 2006; 5 (4): 259-72
10. Clemett D, Lamb HM. Exemestane: a review of its use in postmenopausal women with advanced breast cancer. Drugs 2000 Jun; 59 (6): 1279-96
11. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007 Feb 17; 369 (9561): 559-70
12. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen ther- apy in postmenopausal women with primary breast can- cer. N Eng J Med 2004 Mar 11; 350 (11): 1081-92
13. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol 2000 Apr; 18 (7): 1399-411
14. Aihara T, Hozumi Y, Suemasu K, et al. The effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: preliminary results of N-SAS (National Surgical Adjuvant Study) BC04, the TEAM Japan sub-study [abstract no. 2086]. Breast Cancer Res Treat 2007Dec; 106 Suppl. 1: 114. Plus poster presented at he 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13-16; San Antonio (TX)
15. van Nes JGH, Papapoulos SE, Braun JJ, et al. Effect of exemestane on bone turnover markers and bone mineral density (BMD): 2 year results of the Dutch/Belgian Ta- moxifen Exemestane Adjuvant Multicentre (TEAM) trial [abstract no. 1154]. Cancer Res 2009 Jan 15; 69 (2 Suppl.): 152s
16. McCaig FM, Renshaw L, Williams L, et al. A randomized study of the effects of anastrozole (A), letrozole (L) and exemestane (E) on bone turnover [abstract no. 1145]. Cancer Res 2009 Jan 15; 69 (2 Suppl.): 149s
17. Coleman RE, Banks LM, Girgis S, et al. Reversal of ske- letal effects of endocrine treatments in the intergroup study [abstract no. 1128]. Cancer Res 2009 Jan 15; 69 (2 Suppl.): 144s
18. McCaig FM, Renshaw L, Williams L, et al. A randomized study comparing the effects of anastrozole (A), letrozole (L), exemestane (E) and tamoxifen (T) on coagulation [abstract no. 1132]. Cancer Res 2009 Jan 15; 69 (2 Suppl.): 145s
19. Bertelli G, Hall E, Ireland E, et al. Endometrial status in the Intergroup Exemestane Study up to 2 years post- treatment [abstract no. 2078]. Breast Cancer Res Treat 2007 Dec; 106 Suppl. 1: 111. Plus poster presented at the 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13-16; San Antonio (TX)
20. Wang X, Chen S. Aromatase destabilizer: novel action of exemestane, a food and drug administration-approved aro-matase inhibitor. Cancer Res 2006 Nov 1; 66 (21): 10281-6
21. Lønning PE, Geisler J, Krag LE, et al. Effects of ex-emestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005 Aug 1; 23 (22): 5126-37
22. Montagnani A, Gonnelli S, Cadirni A, et al. The effects on lipid serum levels of a 2-year adjuvant treatment with exemestane after tamoxifen in postmenopausal women with early breast cancer. Eur J Int Med 2008 Dec; 19 (8): 592-7
23. Markopoulos C, Polychronis A, Zobolas V, et al. The effect of exemestane on the lipidemic profile of post- menopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study. Breast Cancer Res Treat 2005 Sep; 93 (1): 61-6
24. Markopoulos C, ChrissochouM,Michailidou A, et al. Effect of exemestane on the lipidemic profile of post-menopausal operable breast cancer patients following 5-7 years of ad- juvant tamoxifen: preliminary results of the ATENA sub- study. Anticancer Drugs 2005 Sep; 16 (8): 879-83
25. FranciniG, PetrioliR,MontagnaniA, et al.Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids. Br J Cancer 2006 Jul 17; 95 (2): 153-8
26. Anker GB, Refsum H, Ueland PM, et al. Influence of aromatase inhibitors on plasma total homocysteine in postmenopausal breast cancer patients. Clin Chem 1999 Feb; 45 (2): 252-6
27. Zilembo N, Noberasco C, Bajetta E, et al. Endocrinological and clinical evaluation of exemestane, a new steroidal aro- matase inhibitor. Br J Cancer 1995; 72 (4): 1007-12
28. Geisler J, King N, Anker G, et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 1998 Sep; 4 (9): 2089-93
29. Johannessen DC, Engan T, Di Salle E, et al. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin Cancer Res 1997 Jul; 3 (7): 1101-8
30. Atalay G, Dirix L, Biganzoli L, et al. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'. Ann Oncol 2004 Feb; 15 (2): 211-7
31. Evans TR, Di Salle E, Ornati G, et al. Phase I and endo- crine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res 1992 Nov 1; 52 (21): 5933-9
32. McClosky EV, Hannon RA, Lakner G, et al. Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastro- zole in healthy postmenopausal women. Eur J Cancer 2007 Nov; 43 (17): 2523-31
33. Geisler J, Lønning PE, Krag LE, et al. Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with ex- emestane: a randomised, placebo-controlled study. Eur J Cancer 2006 Nov; 42 (17): 2968-75
34. Lonn E. Homocysteine in the prevention of ischemic heart isease, stroke and venous thromboembolism: therapeutic target or just another distraction? Curr Opin Hematol 2007 Sep; 14 (5): 481-7
35. Humphrey LL, Fu R, Rogers K, et al. Homocysteine levels and coronary heart disease incidence: a systemic review and meta-analysis. Mayo Clin Proc 2008 Nov; 83 (11): 1203-12
36. Coleman RE, Banks LM, Girgis SI, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Ex- emestane Study (IES): a randomised controlled study. Lancet Oncol 2007 Feb; 8 (2): 119-27
37. Gonnelli S, Cadirni A, Caffarelli C, et al. Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane. Bone 2007 Jan; 40 (1): 205-10
38. Hadji P, ZillerM, Kieback DG, et al. Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised sub- study. Ann Oncol. Epub 2009 Feb 13
39. Hadji P, Ziller M, Kieback DG, et al. The effect of ex- emestane or tamoxifen on markers of bone turnover: results of a German sub-study of the Tamoxifen Exemestane Ad- juvant Multicentre (TEAM) trial. Breast Epub 2009 Apr 11
40. Jones S, Stokoe C, SborovM, et al. The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer. Clin Breast Cancer 2008 Dec; 8 (6): 527-32
41. Spinelli R, Jannuzzo MG, Poggesi I, et al. Pharmacokinetics (PK) of Aromasin- (exemestane, EXE) after single and re- peated doses in healthy postmenopausal volunteers (HPV) [abstract no. 1185]. Eur J Cancer 1999 Sep; 35 Suppl. 4: S295
42. Poggesi I, Jannuzzo MG, Di Salle E, et al. Effect of food and formulation on the pharmacokinetics and pharma- codynamics of a single oral dose of exemestane (Aromasin-, EXE) [abstract no. 741]. Proc Am Soc Clin Oncol 1999; 18: 193a
43. Jannuzzo MG, Spinelli R, Poggesi I, et al. Inhibition of CYP3A4 does not influence Aromasin® (exemestane, EXE) pharmacokinetics (PK) in healthy postmenopausal volunteers (HPV) [abstract no. 1184]. Eur J Cancer 1999 Sep; 35 Suppl. 4: S294
44. Jannuzzo MG, Poggesi I, Spinelli R, et al. The effects of degree of hepatic or renal impairment on the pharmaco- kinetics of exemestane in postmenopausal women. Cancer Chemother Pharmacol 2004 Jun; 53 (6): 475-81
45. MayordomoJ,LlombartA,MartinM,etal.Randomized, multicenter, crossover phase II trial to compare exemestane vs. anastrozole in postmenopausal patients with advanced breast cancer and positive hormone receptors. Final efficacy analysis of GEICAM 2001-03 study [abstract no. 638]. J Clin Oncol 2006 Jun 20; 24 (18 Suppl.): 37
46. Jones SE, Seynaeve C, Hasenburg A, et al. Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective random- ized phase III trial in hormone sensitive postmenopausal early breast cancer [abstract no. 15 plus presentation]. San Antonio Breast Cancer Symposium 2008 Dec 10-14; San Antonio (TX)
47. Paridaens RJ, Dirix LY, Beex LV, et al. Phase III study comparing exemestane with tamoxifen as first-line hormo- nal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 2008 Oct 20; 26 (30): 4883-90
48. Chia S, Gradishar W, Mauriac L, et al. Double-blind, randomized placebo controlled trial of fulvestrant com- pared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hor- mone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 2008 Apr 1; 26 (10): 1664-70
49. Chernozemsky I, Kalinov K, Tzekov H, et al. Randomized phase III trial of exemestane or tamoxifen in first-line hormonal treatment of postmenopausal women with me- tastatic breast cancer [abstract no. 2101]. Breast Cancer Res Treat 2007 Dec; 106 Suppl. 1: 119
50. Mamounas EP, Jeong JH, Wickerham DL, et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial. J Clin Oncol 2008 Apr 20; 26 (12): 1965-71
51. Fallowfield LJ, Bliss JM, Porter LS, et al. Quality of life in the Intergroup Exemestane Study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 2006 Feb 20; 24 (6): 910-7
52. Fallowfield LJ, Langridge CI, Kilburn LS, et al. Quality of life in the Intergroup Exemestane Study 5 years post- randomisation [abstract no. 1091]. Breast Cancer Res Treat 2007 Dec; 106 Suppl. 1: 73. Plus poster presented at the 30th San Antonio Breast Cancer Symposium; 2007 Dec 13-17; San Antonio, (TX)
53. vanNes JGH, VoskuilDW, van Leeuwen FE, et al. Quality of life in relation to hormonal treatment of post- menopausal women in the Dutch Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial [abstract no. 21]. Cancer Res 2009 Jan 15; 69 (2 Suppl.): 69s
54. Laffaioli RV, Formato R, Tortoriello A, et al. Phase II study of sequential hormonal therapy with anastrozole/ exemestane in advanced andmetastatic breast cancer. Br J Cancer 2005; 92 (9): 1621-5
55. Thurlimann B, Paridaens R, Serin D, et al. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Eur J Cancer 1997 Oct; 33 (11): 1767-73
56. Gennatas C, Michalaki V, Carvounis E, et al. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on le- trozole or anastrozole. A phase II trial conducted by the Hellenic Group of Oncology (HELGO). Tumori 2006 Jan-Feb; 92 (1): 13-7
57. Jones S, Vogel C, Arkhipov A, et al. Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. J Clin Oncol 1999 Nov; 17 (11): 3418-25
58. Kvinnsland S, Anker G, Dirix LY, et al. High activity and tolerability demonstrated for exemestane in post- menopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment. Eur J Cancer 2000 May; 36 (8): 976-82
59. Lønning PE, Bajetta E, Murray R, et al. Activity of ex- emestane in metastatic breast cancer after failure of non- steroidal aromatase inhibitors: a phase II trial. J Clin Oncol 2000 Jun; 18 (11): 2234-44
60. Bertelli G, Garrone O, Merlano M, et al. Sequential treat- ment with exemestane and non-steroidal aromatase inhibi- tors in advanced breast cancer. Oncology 2005; 69 (6): 471-7
61. Campos SM, Guastalla JP, Subar M, et al. A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. Clin Breast Cancer 2009 Feb; 9 (1): 39-44
62. Chia S, Piccart M, Gradishar W, et al. Fulvestrant vs ex- emestane following non-steroidal aromatase inhibitor failure: first overall survival data from the EFECT trial [abstract no. 2091]. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13-16; San Antonio (TX)
63. Paridaens R, Dirix L, Lohrisch C, et al.Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for post- menopausal women with metastatic breast cancer. Ann Oncol 2003 Sep; 14 (9): 1391-8
64. US National Institutes of Health. Providing information regarding several clinical trials that are planned/ongoing/ ompleted [online]. Available from URL: http://www.clini caltrials.gov [Accessed 2008 Sep 25]
65. Jones SE, Cantrell J, Vukelja S, et al. Comparison of meno- pausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy. J Clin Oncol 2007 Oct 20; 25 (30): 4765-71
66. Gil JM, Rubio-Terres C, Del Castillo A, et al. Pharmaco- economic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer. Clin Transl Oncol 2006May; 8 (5): 339-48
67. Lundkvist J,Wilking N,Holmberg S, et al. Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden. Breast Cancer Res Treat 2007May; 102 (3): 289-99
68. Skedgel C, Rayson D, Dewar R, et al. Cost-utility of adjuvant hormone therapies for breast cancer in post- menopausal women: sequential tamoxifen-exemestane and upfront anastrozole. Breast Cancer Res Treat 2007 Mar; 101 (3): 325-33
69. Skedgel C, RaysonD,Dewar R, et al. Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-me- nopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen- letrozole. Breast 2007 Jun; 16 (3): 252-61
70. Thompson D, Taylor DC,Montoya EL, et al. Cost-effective- ness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer. Value Health 2007 Sep-Oct; 10 (5): 367-76
71. Coombes RC, Hall E, Snowdon CF, et al. The Intergroup Exemestane Study: a randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen - updated survival analysis [abstract no. 3]. Breast Cancer Res Treat 2004; 88 Suppl. 1: 7
72. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005 Jan; 365 (9453): 60-2
73. BaumM, Buzdar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial [published erratum appears in Lancet 2002; 360 (9344): 152]. Lancet 2002; 359 (9324): 2131-9
74. BaumM, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early- stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003 Nov; 98 (9): 1802-10
75. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003 Nov 6; 349 (19): 1793-802
76. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant ther- apy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005 Sep; 97 (17): 1262-71
77. Gould RE, Garcia AA. Update on aromatase inhibitors in breast cancer. Curr Opin ObstetGynecol 2006 Feb; 18 (1): 41-6
78. Gradishar WJ. Tamoxifen: what next? Oncologist 2004; 9 (4): 378-84
79. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer 2009 [online]. Available from URL: http://misc.medscape.com/images/ 586/406/Breast-Medscape.pdf [Accessed 2009 Apr 28]
80. Thorne C. Management of arthralgias associated with aromatase inhibitor therapy. Curr Oncol 2007 Dec; 14 Suppl. 1: S11-9
81. Buzdar AU, Coombes RC, Goss PE, et al. Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer. Cancer 2008 Dec; 112 Suppl. 3: 700-9
82. Wheler J, Johnson M, Seidman A. Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy. Semin Oncol 2006 Dec; 33 (6): 672-80
83. Pestalozzi B, CastiglioneM. Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008 May; 19 Suppl. 2: ii7-10
84. Goldhirsch A, Wood WC, Gelber RD, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007 Jul; 18 (7): 1133-44
85. Sanford M, Plosker GL. Anastrozole: a review of its use in postmenopausal women with early-stage breast cancer. Drugs 2008; 68 (9): 1319-40
86. AstraZeneca UK Ltd. Arimidex® 1mg film-coated tablets: summary of product characteristics [online]. Available from URL: http://www.emc.medicines. org.uk [Accessed 2009 Apr 28]
87. Mouridsen HT, Giobbie-Hurder A, Mauriac L, et al. BIG 1-98: a randomized double-blind phase III study evaluat- ing letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer [abstract no. 13]. Cancer Res 69 (2 Suppl.): 66s
88. Novartis Pharmaceuticals UK Ltd. Femara- 2.5mg tablets: summary of product characteristics [online]. Available from URL: http://www.emc.medicines. org.uk [Accessed 2009 Apr 28]
89. AstraZeneca Pharmaceuticals LP. Arimidex® (anastrozole) tablets: US prescribing information [online]. Available from URL: http://www.fda.gov/cder/ foi/label/2008/ 020541s020s021s023lbl.pdf [Accessed 2009 Mar 13]
90. Novartis Pharmaceuticals Corporation. Femara® (le- trozole) 2.5mg tablets: US prescribing information [on- line]. Available from URL: http://www.fda.gov/cder/foi/ label/2007/020726s014lbl.pdf [Accessed 2008 Sep 22]
91. Kataja V, Catiglione M. Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diag- nosis, treatment and follow-up. Ann Oncol 2008 May;19 Suppl. 2: ii11-3
92. National Breast and Ovarian Cancer Centre. Re- commendations for use of endocrine therapy for the treatment of hormone receptor-positive advanced breast cancer [online]. Available from URL: http://www.nbocc. org.au/bestpractice/ resources/ETAG-recommendationsforus. pdf [Accessed 2008 Sep 25]
93. Goss PE, Strasser K. Tamoxifen resistant and refractory breast cancer. The value of aromatase inhibitors. Drugs 2002; 62 (6): 957-66
94. Lønning PE. Is there a growing role for endocrine therapy in the treatment of breast cancer? Drugs 2000 Jul; 60 (1): 11-21
95. Carlini P, Bria E, Giannarelli D, et al. New aromatase inhibitors as second-line endocrine therapy in post- menopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials. Cancer 2005 Oct 1; 104 (7): 1335-42
96. AstraZeneca UK Ltd. Faslodex: summary of product characteristics [online]. Available from URL: http:// www.emea.europa.eu/humandocs/PDFs/EPAR/ faslodex/ H-540-PI-en.pdf [Accessed 2009 Mar 13]
97. AstraZeneca Pharmaceuticals LP. Faslodex (fulvestrant) injection: US prescribing information [online]. Avail- able from URL: http://www.fda.gov/cder/ foi/label/2005/ 021344s004lbl.pdf [Accessed 2008 Sep 26]
98. Perez EA. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Ann Oncol 2007; 18 Suppl. 8: viii26-35
99. Conte P, Frassoldati A. Aromatase inhibitors in the ad- juvant treatment of postmenopausal women with early breast cancer: putting safety issues into perspective. Breast J 2007 Jan-Feb; 13 (1): 28-35
100. Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in post- menopausal women with early breast cancer. J Clin Oncol 2007 Mar 1; 25 (7): 829-36
101. Lønning PE. Exemestane for breast cancer prevention: afeasible strategy? Clin Cancer Res 2005 Jan 15; 11 (2 Pt 2): 9 18-24s